Double-Punch cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07236151
Summary
This study tested a two-part treatment for adults with aggressive large B-cell lymphoma that has returned or not responded to prior therapy. First, patients received a transplant of their own blood-forming stem cells. Within a week, they then received two infusions of their own genetically modified immune cells (CAR-T cells), designed to attack the cancer. The goal was to see if this powerful combination could eliminate the cancer and was safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.